ABEONA THERAPEUTICS INC.: Diferență între versiuni

De la TradeVille.ro wiki
(Pagină nouă: Pagina dedicata companiei ABEONA THERAPEUTICS INC. listata cu simbolurile US.ABEO, US.ABEOc ==Descriere companie== Abeona Therapeutics Inc. (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, wh...)
 
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).)
 
(Nu s-a afișat o versiune intermediară efectuată de același utilizator)
Linia 1: Linia 1:
Pagina dedicata companiei ABEONA THERAPEUTICS INC. listata cu simbolurile US.ABEO, US.ABEOc
Pagina dedicata companiei [[Abeona Therapeutics Inc.|ABEONA THERAPEUTICS INC.]] listata cu simbolurile US.ABEO, US.ABEOc


==Descriere companie==
==Descriere companie==
Abeona Therapeutics Inc.  (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.
[[Abeona Therapeutics]] Inc.  (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.


==Grafic actiuni companie==
==Grafic actiuni companie==

Versiunea curentă din 23 noiembrie 2024 20:53

Pagina dedicata companiei ABEONA THERAPEUTICS INC. listata cu simbolurile US.ABEO, US.ABEOc

Descriere companie[edit | ]

Abeona Therapeutics Inc. (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

Grafic actiuni companie[edit | ]

Ultimele stiri despre ABEONA THERAPEUTICS INC. (US.ABEO)[edit | ]

Ultimele stiri despre ABEONA THERAPEUTICS INC. (US.ABEOc)[edit | ]